Equities

NuCana PLC

NuCana PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.75
  • Today's Change0.180 / 7.01%
  • Shares traded9.36k
  • 1 Year change-86.75%
  • Beta0.9927
Data delayed at least 15 minutes, as of Jul 03 2024 17:28 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

  • Revenue in USD (TTM)0.00
  • Net income in USD-33.94m
  • Incorporated1997
  • Employees25.00
  • Location
    NuCana PLCLochside House, 3 Lochside WayEDINBURGH EH12 9DTUnited KingdomGBR
  • Phone+44 131 248 3660
  • Fax+44 131 248 3001
  • Websitehttps://www.nucana.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioCardia Inc468.00k-10.34m5.44m16.00------11.63-7.04-7.040.3132-1.270.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
Tron Pharmaceuticals Inc1.01m-549.47k5.50m50.00------5.45-0.0034-0.00340.0062-0.0508------20,191.00--------60.28---110.51--0.0417-433.32----0.3272---39.70------
Fresh Tracks Therapeutics Inc8.01m-5.69m5.55m4.00--0.5591--0.6934-1.38-1.381.491.660.7326----2,001,500.00-52.10-89.76-66.50-115.24-----71.12-442.61---1,272.000.00--15.3137.6273.02------
Hepion Pharmaceuticals Inc0.00-38.52m5.58m22.00--0.9582-----9.49-9.490.001.370.00----0.00-117.64-61.43-145.05-68.82-----------3,240.310.00-------7.92------
TFF Pharmaceuticals Inc885.71k-19.93m5.61m19.00--0.8596--6.33-10.20-10.200.43712.110.0647--3.7246,616.32-145.46-79.57-181.57-83.41-----2,249.83-8,687.66----0.00--48.01--33.13------
HST Global Inc0.00-141.11k5.72m1.00---------0.0269-0.02690.00-0.11930.00-------29,397.92-5,836.01---------------24.24---------0.7858------
Intelligent Bio Solutions Inc2.83m-10.03m5.74m17.00--0.4816--2.03-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Transcode Therapeutics Inc0.00-17.06m5.75m10.00--1.10-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Xenetic Biosciences Inc2.44m-4.47m5.77m4.00--0.6648--2.36-2.92-2.921.595.630.2116----611,240.00-38.71-48.91-41.54-52.82-----182.95-682.42----0.00--48.80--36.90------
CeCors Inc-100.00bn-100.00bn5.81m6.00---------------0.0163------------------------------------22.70------
Burzynski Research Institute Inc0.00-1.34m5.83m2.00---------0.0102-0.01020.00-0.00020.00-------62,992.45-15,304.89-------------------------45.74------
NuCana PLC (ADR)0.00-33.94m5.85m25.00--0.4868-----303.31-303.310.005.680.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Ainos Inc93.68k-14.56m5.91m46.00--0.2547--63.06-3.27-3.270.02063.690.00280.81331.622,036.52-43.83-36.36-48.64-58.33-222.1136.82-15,547.49-813.630.2847-75.230.2003---96.539.461.69--66.44--
Cyclerion Therapeutics Inc0.00-10.95m6.11m1.00--0.568-----4.380.29040.003.970.00----0.00-95.95-72.70-158.12-86.96-------2,565.62----0.00---100.00--30.98------
Tenax Therapeutics Inc0.00-10.10m6.23m5.00--0.501-----24.52-24.520.006.350.00----0.00-67.96-199.16-75.66-285.64-----------105.120.0322------30.21------
Kazia Therapeutics Ltd (ADR)15.18k-13.77m6.29m12.00--0.5936--414.27-0.835-0.8350.00080.35550.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Data as of Jul 03 2024. Currency figures normalised to NuCana PLC's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.